DDInter1321 DDInter1819
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Ocrelizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enfortumab vedotin
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Ocrelizumab {u} may lead to a major life threatening interaction when taken with {v} Bacillus calmette-guerin substrain tice live antigen
Ocrelizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib